Clinical trial Recruiting at 12 sites Observational Ages 4 and up

MORC2 gene changes and how they relate to nerve and developmental symptoms

Official title: Deciphering MORC2 Genotype/Phenotype Correlation to Improve Patient Diagnostic

Run by Hospices Civils de Lyon · NCT07038239 · Data updated 2026-11-12

This project will try to see if specific changes in the MORC2 gene explain why some people develop Charcot–Marie–Tooth nerve problems while others have broader developmental delays, growth impairment, facial differences, and neuropathy.

Quick facts

Study typeObservational
Ages4 Years and up
SexAll
Enrollment45 (estimated)
SponsorHospices Civils de Lyon
Academic / other
Locations12 sites (Besançon and 11 other locations)
StatusRecruiting
StartedJune 16, 2026
Main results expectedJune 2027
Study endsJune 2027
Registry record updatedJune 18, 2026
Trial IDNCT07038239 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People of any age who have a confirmed MORC2 mutation, can provide informed consent (or have guardian consent), and have undergone or can undergo EMG and biological sample collection are the intended participants.

Probably not a fit

Patients who lack a MORC2 mutation, have another identified genetic cause, refuse sample collection, or fall under the regulatory exclusions (for example pregnancy or legal deprivation of liberty) will not be eligible and are unlikely to benefit from this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational genotype–phenotype correlation project enrolling people with confirmed MORC2 mutations. Participants undergo clinical evaluation, electromyography (EMG) as available, and provide blood and skin biopsy samples for molecular studies. Investigators will compare clinical presentations across different MORC2 variants and examine how those variants affect MORC2-related functions such as ATPase activity and HUSH-complex–mediated chromatin silencing. The goal is to link specific genetic changes to the spectrum from isolated peripheral neuropathy to the broader DIFGAN phenotype.

Why it matters

Potential benefit: If successful, the findings could help clinicians predict prognosis and personalize monitoring for people with MORC2 mutations and point to molecular pathways for future therapies.

How similar studies have gone: Over 30 families with MORC2 mutations have been reported linking the gene to CMT and to broader DIFGAN presentations, but detailed genotype–phenotype mapping and mechanistic links via HUSH activity remain incompletely defined.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Presence of a mutation in the MORC2 gene, identified during an evaluation for peripheral neuropathy or intellectual disability
* Patient has undergone electromyography (EMG) or is able to undergo EMG during the inclusion visit
* Affiliation with the national health insurance system
* Informed consent from the patient if an adult, or from parents/legal guardians if the patient is a minor

Exclusion Criteria:

* Presence of another mutation responsible for peripheral neuropathy or intellectual disability
* Refusal to undergo biological sample collection
* Regulatory exclusion criteria:
* Pregnant, postpartum, or breastfeeding women
* Individuals deprived of liberty by judicial or administrative decision
* Individuals not affiliated with a social security system or not benefiting from an equivalent health coverage scheme

Where it's running

  • CHU de Besançon
    Besançon, France
    Recruiting
  • CHRU Brest
    Brest, France
    Recruiting
  • CHU Grenoble
    Grenoble, France
    Recruiting
  • CH de Versailles
    Le Chesnay, France
    Recruiting
  • Service de Génétique moléculaire, pharmacogénétique, hormologie Hôpital Bicêtre
    Le Kremlin-Bicêtre, France
    Recruiting
  • Hospices Civils de Lyon
    Lyon, France
    Recruiting
Show 6 more locations
  • CHU Marseille
    Marseille, France
    Recruiting
  • CHU de Nantes
    Nantes, France
    Recruiting
  • CH Pitié Salpêtrière
    Paris, France
    Recruiting
  • Hôpital Necker
    Paris, France
    Recruiting
  • CHU de Saint-Etienne
    Saint-Etienne, France
    Recruiting
  • CHU Strasbourg
    Strasbourg, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.